top of page

Biopharma Daily Stock Updates - 03/15/22

$XBI $82.26 | +1.47%


Covid Updates

$PFE 0.0% Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults source

Pipeline Updates

$WVE +4.3% Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings. Source

$ALEC -3.6% Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial. source

$EYEN +1.5% Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions. source

$PDSB +7.5% PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers. source

$CHRS +4.0% Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series. source

$SAGE +2.2% Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease. source

$IDYA -2.3% IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data. source

Business Updates

$PCRX 0.0% Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022. source

$PASG +1.4% Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway. source


Posted by FS/JM

bottom of page